Gabriele Doering

676 total citations
6 papers, 202 citations indexed

About

Gabriele Doering is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Reproductive Medicine. According to data from OpenAlex, Gabriele Doering has authored 6 papers receiving a total of 202 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Reproductive Medicine. Recurrent topics in Gabriele Doering's work include Advanced Breast Cancer Therapies (3 papers), Cancer Treatment and Pharmacology (2 papers) and PARP inhibition in cancer therapy (2 papers). Gabriele Doering is often cited by papers focused on Advanced Breast Cancer Therapies (3 papers), Cancer Treatment and Pharmacology (2 papers) and PARP inhibition in cancer therapy (2 papers). Gabriele Doering collaborates with scholars based in Germany and Poland. Gabriele Doering's co-authors include Klaus Krueger, Stanisław Sierakowski, Frank Buttgereit, Erika Gromnica‐Ihle, Jacek Szechiński, R. Alten, Sławomir Jeka, Andreas Kuznik, Dirk Stengel and W. Schroeder and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Annals of the Rheumatic Diseases.

In The Last Decade

Gabriele Doering

6 papers receiving 189 citations

Peers

Gabriele Doering

ONCOL

RM

RHEUM

SURGE

MB

Andrzej Witek Poland

Maren Keller Germany

Dagmara Klasa-Mazurkiewicz Poland

Naïri Tchrakian Canada

Marie Karlíková Czechia

Bangbei Wan China

Daniel Herr Germany

C J Lips Netherlands

J. Gillen United States

Kohei Kato Japan

Andrzej Witek Poland

Gabriele Doering

37 ×0.5

ONCOL

51 ×0.7

RM

28 ×0.6

RHEUM

25 ×0.7

SURGE

102 ×2.9

MB

Citations per year, relative to Gabriele Doering Gabriele Doering (= 1×) peers Andrzej Witek

Countries citing papers authored by Gabriele Doering

Since Specialization

Citations

This map shows the geographic impact of Gabriele Doering's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabriele Doering with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabriele Doering more than expected).

Fields of papers citing papers by Gabriele Doering

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gabriele Doering. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabriele Doering. The network helps show where Gabriele Doering may publish in the future.

Co-authorship network of co-authors of Gabriele Doering

This figure shows the co-authorship network connecting the top 25 collaborators of Gabriele Doering. A scholar is included among the top collaborators of Gabriele Doering based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gabriele Doering. Gabriele Doering is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Hauke, Jan, Corinna Ernst, Peter A. Fasching, et al.. (2020). 176P Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332). Annals of Oncology. 31. S313–S313. 3 indexed citations

2.

Fasching, Peter A., Christian Jackisch, Kerstin Rhiem, et al.. (2019). GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD).. Journal of Clinical Oncology. 37(15_suppl). 506–506. 34 indexed citations

3.

Sehouli, Jalid, Felix Hilpert, Sven� Mahner, et al.. (2016). Topotecan (T) ± sorafenib (S) in platinum-resistant ovarian cancer (PROC): A double-blind placebo-controlled randomized NOGGO–AGO intergroup Trial—TRIAS.. Journal of Clinical Oncology. 34(15_suppl). 5522–5522. 2 indexed citations

4.

Loibl, Sibylle, Gabriele Doering, Lothar Müller, et al.. (2011). Multicenter Phase II Study with Weekly Bendamustine and Paclitaxel as First- or Later-Line Therapy in Patients with Metastatic Breast Cancer: RiTa II Trial. Breast Care. 6(6). 457–461. 1 indexed citations

5.

Buttgereit, Frank, Gabriele Doering, Stanisław Sierakowski, et al.. (2010). Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Annals of the Rheumatic Diseases. 69(7). 1275–1280. 86 indexed citations

6.

Sehouli, Jalid, Dirk Stengel, Philipp Harter, et al.. (2010). Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. Journal of Clinical Oncology. 29(2). 242–248. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact